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This is a brief review of some of the mechanisms by which members of
the large family of chemotactic cytokines (known as chemokines)
participate in critical features of lung cancer biology.
(J Thorac Oncol. 2006;1: 287–288)
Chemokines are a family of small (8–12 kDa) cytokinesconsisting of four subfamilies defined by the configura-
tion of the first two of four conserved cysteine residues (C,
CC, CXC, and CXXXC families).1 Chemokines were initially
studied for their ability to recruit specific subpopulations of
leukocytes. However, research shows that many if not most
of the members of the CC and CXC chemokine families are
involved in mediating critical features of tumor biology, such
as cell growth, angiogenesis, and metastasis, in addition to
regulating tumor immunity. In this review, we briefly outline
some of the mechanisms by which chemokines participate in
two aspects of tumor biology, angiogenesis and metastasis.
The CXC chemokines can be divided into members that
promote angiogenesis (all of which have in common the
glutamic acid-leucine-arginine sequence, the “ELR motif,”
immediately preceding the first cysteine in the NH3-terminus;
the ELR-CXC chemokines), and those that can directly in-
hibit angiogenesis (which, interestingly, are the inter-
feron-inducible CXC chemokines CXCL9, CXCL10, and
CXCL11). These angiostatic CXC chemokines may mediate
many of the antiangiogenic and antitumor immune effects of
interferons, a phenomenon referred to as “immunoangiosta-
sis” by Strieter et al.2 This dichotomy in the CXC chemokine
family makes them unique among cytokines that regulate
angiogenesis. We and others have shown that the ELR-CXC
chemokines are major sources of angiogenic activity in non-
small cell lung cancer, and that their expression in tumor
homogenates correlates strongly with the vascularity of the
corresponding tissue section.3–6
Many studies have shown that a transcription factor,
nuclear factor kappa-B (NFB), is constitutively activated in
cancer cells.7 This NFB activity in lung cancer cells is
critical to the constitutive production of angiogenic CXC
chemokines by malignant cells.8 Importantly, nonmalignant
cells also play a role in promoting angiogenesis. Macro-
phages and fibroblasts within the tumor are also activated
(both by cell-matrix adhesive interactions and by soluble
factors present within the tumor) to produce significant quan-
tities of angiogenic CXC chemokines.9–11 A critical report by
Addison and colleagues showed that the endothelial receptor
through which CXC chemokines induce angiogenesis is
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FIGURE 1. (A) Angiogenic CXC chemokines (bullet shaped)
derived from both malignant cells and tumor-infiltrating
stromal cells induce angiogenesis by binding to CXCR2
present on tumor endothelium. (B) Stromal cell-derived fac-
tor 1 (now known as CXCL12) is constitutively produced in
lymph nodes, liver, bone marrow, and the adrenal gland.
This results in preferential “recruitment” to these organs of
circulating tumor cells that express CXCR4.
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CXCR2.12,13 In summary, ELR-CXC chemokines are an
important source of angiogenic activity in lung cancer, and
their expression is the net result of secretion by both malig-
nant cells and infiltrating “normal” cells in the tumor stroma
(Figure 1 A).
One of the more intriguing recent findings in this field
is the discovery that specific chemokine ligand-receptor pairs
dictate the organ-specific metastatic patterns of both breast
and lung cancer.14,15 In lung cancer, Phillips and colleagues
showed that non-small cell lung cancer tumors and cell lines
express the chemokine receptor CXCR4. Interestingly,
CXCL12, the ligand for CXCR4, is constitutively expressed
in the same tissues to which lung cancers preferentially
metastasize (Figure 1 B). Antibody-mediated inhibition of
CXCR4 in a mouse model of lung cancer dramatically re-
duced the incidence of tumor metastases.15
This topic covers only a small proportion of the exten-
sive overlap between the disciplines of chemokine and tumor
biology. Chemokines can also act as growth factors16,17 and
regulators of tumor immunity.2 For a more in-depth review,
see Balkwill.18 The fundamental role(s) of chemokine ligand-
receptor interactions in tumor biology suggests that targeting
this biology is an important potential therapeutic opportunity
for lung cancer. Therapeutic opportunities include ap-
proaches that target chemokines by blocking the proangio-
genic chemokine receptor CXCR2 and/or the metastasis-
promoting ligand receptor pair CXCL12/CXCR4. In addition,
the interferon-inducible chemokines CXCL9, CXCL10, and
CXCL11 should be explored as therapeutic agents themselves
for their angiostatic and immunologic potential (immunoan-
giostasis of tumors). Each of these strategies has a sound
rationale supported by current animal models and awaits
further exploration at the level of human trials.
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